German Drug Industry Growth Is Slowing

15 January 1996

German pharmaceutical industry growth in first-half 1995 was not sustained in the second half of the year, and the main drug industry association, the BPI, reports that the pharmacy market only reached 1992 volume sales levels last year.

The BPI adds that the hopes of drug makers that 1995 would see a widespread recovery of drug sales in volume and price terms were not fulfiled. The association gives as reasons for the 1995 situation a marked wave of colds and flu in the spring of 1995, which triggered high first-half sales but also generated a later downturn in prescriptions because of fears among doctors that they would exceed their fixed drug budgets.

Strong DM Impacts Orders A further factor affecting 1995 results was that foreign orders declined compared with 1994, reportedly in reaction to the strong Deutschemark.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight